Royalty Pharma (RPRX) Accumulated Expenses (2020 - 2026)

Royalty Pharma has disclosed Accumulated Expenses across 7 years of filings, most recently posting $25.3 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $25.3 million, up 31.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.3 million (up 31.64% YoY), and the FY2025 annual result was $110.8 million, up 13.01% from the prior year.
• Accumulated Expenses came in at $25.3 million for Q1 2026 at Royalty Pharma, down from $110.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $110.8 million in Q4 2025 to a low of $12.6 million in Q3 2023.
• The 5-year median for Accumulated Expenses is $38.4 million (2024), against an average of $43.6 million.
• Across the five-year window, Accumulated Expenses soared 204.98% in 2024 and retreated 24.39% in 2025, its largest moves.
• Royalty Pharma's Accumulated Expenses stood at $54.2 million in 2022, then declined by 4.58% to $51.7 million in 2023, then soared by 89.74% to $98.1 million in 2024, then climbed by 13.01% to $110.8 million in 2025, then tumbled by 77.17% to $25.3 million in 2026.
• The last three Accumulated Expenses figures came in at $25.3 million (Q1 2026), $110.8 million (Q4 2025), and $29.0 million (Q3 2025), per Business Quant data.